Your session is about to expire
← Back to Search
RSV MAT for Respiratory Syncytial Virus
Study Summary
This trial was testing a potential vaccine for RSV, and has been stopped due to safety concerns.
- Respiratory Syncytial Virus (RSV)
- Respiratory Syncytial Virus
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Would this research project be able to consider individuals who are 50 and older?
"This research study is looking for participants who are under the age of 50 and have already celebrated their 15th birthday."
Has the RSV MAT vaccine been cleared by the FDA?
"Since this is a Phase 3 trial, RSV MAT has been deemed safe by our team at Power. This level of safety is based on both efficacy data and multiple rounds of supportive safety data."
Could you explain the requirements for participants in this research project?
"This study aims to enroll 367 people between the ages of 15 and 49 who have respiratory syncytial virus infections. In addition, patients must meet the following criteria: they must be a maternal participant, they must be able and willing to comply with the requirements of the protocol, they must provide consent for both their own participation and the participation of their infant after birth (or express willingness to consider permitting the infant to take part after birth if local regulations/guidelines require parent(s) to provide additional informed consent after the infant's birth), both mother and father should consent if local regulations / guidelines require it, their pre-"
Share this study with friends
Copy Link
Messenger